Fewer than half of new drugs have data on their comparative benefits and harms against existing treatment options at the time of regulatory approval in Europe and the US. Even when active comparator trials do exist, they might not produce meaningful data to inform decisions in clinical practice and health policy. In this webinar, Dr. Huseyin Naci from the London School of Economics and Political Science will present the key recommendations from the Lancet Series of Comparative Effectiveness. This Series outlined the ethical implications of poor comparative effectiveness evidence, and the changes to the current approval systems that would be required to ensure that patients, clinicians, payers, and other stakeholders in health care systems have timely access to the comparative data they need for decision making.
Info about the speaker Huseyin Naci link
For information please contact email@example.com